DAX23.991 +0,5%Est505.552 +0,4%MSCI World4.308 ±0,0%Top 10 Crypto16,05 +1,3%Nas22.660 +0,3%Bitcoin99.199 +2,1%Euro1,1730 -0,1%Öl65,90 -1,7%Gold3.888 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 Wolfspeed A41JEH RENK RENK73 NVIDIA 918422 Lufthansa 823212 HENSOLDT HAG000 Novo Nordisk A3EU6F Alibaba A117ME Tesla A1CX3T Siemens Energy ENER6Y Deutsche Telekom 555750 BYD A0M4W9 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown: DAX steigt zum Oktoberstart -- VW mit zahlreichen Entlassungen in 2025 -- DroneShield, Wolfspeed, Gold, Rheinmetall, RENK, HENSOLDT, Danone und Lifeway im Fokus
Top News
QUALCOMM gewinnt vor Gericht im Lizenzstreit gegen Arm - So reagieren die Aktien QUALCOMM gewinnt vor Gericht im Lizenzstreit gegen Arm - So reagieren die Aktien
NEU: finanzen.net MSCI World ETF - weltweite Chancen, minimale Kosten NEU: finanzen.net MSCI World ETF - weltweite Chancen, minimale Kosten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
110,20 EUR -1,70 EUR -1,52 %
FSE
131,74 USD +2,75 USD +2,13 %
BTT
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.6,65 Mrd. EUR

KGV14,24Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psy...
PR NewswireModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Wer­bungJazz Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
PR NewswireJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
PR NewswireJazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
PR NewswireJazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
PR NewswireJazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell ...
PR NewswireJazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...
PR NewswireJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated ...
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Aca...
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.